Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Denali Therapeutics Inc. before investing.

In this article, we go over a few key elements for understanding Denali Therapeutics Inc.’s stock price such as:

• Denali Therapeutics Inc.’s current stock price and volume
• Why Denali Therapeutics Inc.’s stock price changed recently
• Upgrades and downgrades for DNLI from analysts
• DNLI’s stock price momentum as measured by its relative strength

About Denali Therapeutics Inc. (DNLI)

Before we jump into Denali Therapeutics Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson’s and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company’s OTV programs also comprise DNL628 targeting tau for Alzheimer’s disease; and DNL422 targeting alpha synuclein for Parkinson’s disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer’s disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Want to learn more about Denali Therapeutics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Denali Therapeutics Inc..

What Caused Denali Therapeutics Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 30, 2026, there was 1 analyst who downgraded Denali Therapeutics Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Denali Therapeutics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Denali Therapeutics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Denali Therapeutics Inc. (DNLI) by visiting AAII Stock Evaluator.

Relative Price Strength of Denali Therapeutics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 30, 2026, Denali Therapeutics Inc. has a weighted four-quarter relative price strength of -4.06%, which translates to a Momentum Score of 42 and is considered to be Average.

Want to learn more about how Denali Therapeutics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Denali Therapeutics Inc. Stock Price: Bottom Line

As of May 1, 2026, Denali Therapeutics Inc.’s stock price is $18.550, which is down 0.91% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Denali Therapeutics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.